Skip to main content
BioMed Research International logoLink to BioMed Research International
. 2026 May 6;2026:8304153. doi: 10.1155/bmri/8304153

Multiomics Approaches for Bacteriophage‐Based Biocontrol Applications: A Review of Metabolomics, Transcriptomics, and Proteomics

Daniel Jesuwenu Ajose 1,✉, Collins Njie Ateba 1,2,✉
Editor: Poorani Gurumallesh Prabu
PMCID: PMC13148639  PMID: 42090420

Abstract

The emergence of multidrug‐resistant (MDR) in various microorganisms due to prolonged antibiotic treatment poses a growing worldwide health issue. It is essential to identify alternative, effective methods to address MDR bacterial diseases, as treating infections caused by these pathogens can be challenging. Bacteriophages, also known as phages, are viruses that target and destroy bacteria. They are being investigated and utilized as alternatives to existing therapies because of their effectiveness and specificity. Phages are often considered safe substitutes for antibiotics because they naturally occur in the environment. Phage replacement therapy involves complex biological processes driven by interactions between phages and bacteria. An integrative approach is essential for a comprehensive analysis of these processes and for understanding the relationships between different biomolecules and their functions. This includes combining data from various omics, such as transcriptomics, proteomics, and metabolomics. High‐throughput technology has revolutionised research, enabling the development of numerous tools and methods for integrating and interpreting multiomics data from diverse samples. This paper presents an overview of omics technologies and highlights strategies for integrating them across layers. By comparing data from multiomics and single‐omics studies, a deeper understanding of the information flow underlying phage therapy will be gained.

Keywords: antibiotics, bacteria–phage interaction, drug resistance, multiomics, next-generation sequencing, phage therapy

1. Introduction

The discovery of antibiotics stands as one of the most pivotal medical advancements of the 20th century, serving as an essential instrument in the treatment and prevention of diseases affecting both humans and animals [1, 2]. Nevertheless, the careless application of antibiotics across various domains of One‐Health, coupled with concerns about antibiotic resistance in bacterial pathogens, has sparked heightened interest in imposing global restrictions on antibiotic use. Given the shortcomings of traditional antimicrobial agents, it is noteworthy that only 15 novel antibiotics have been introduced clinically since 2000. Furthermore, there have been accounts of resistance to certain newly developed antibiotics. This has prompted an exploration of alternative strategies, including phage therapy, to address the challenge posed by antimicrobial‐resistant pathogens [1, 3].

Phage therapy is the use of bacteriophages (phages), viruses that selectively infect and eliminate bacteria, as a therapeutic approach for bacterial illnesses. This strategy holds significant importance in combating antibiotic‐resistant microorganisms [4, 5]. The isolation of phages from natural habitats or their engineering to selectively target bacterial strains enables a more individualized approach to therapy. Phages exhibit a high degree of specificity towards their bacterial targets by attaching to bacterial cells, introducing their genetic material, and interacting with the bacteria’s machinery to undergo replication. This process ultimately results in the annihilation of the bacterial cell [6]. The high specificity of phages enables them to selectively target pathogenic bacteria while preserving the integrity of beneficial bacteria, providing a notable advantage over broad‐spectrum antibiotics. Many bacteria have developed resistance mechanisms against traditional antibiotics, rendering these therapies obsolete. With the ongoing increase in antibiotic resistance, phage therapy offers a highly promising option [7].

Although phage therapy has a lengthy history tracing back to the early 20th century, it has recently regained prominence due to the escalating issue of antibiotic resistance [1, 8]. Contemporary progress in omics technologies and biotechnology has enhanced our capacity to create and implement phage therapeutics, despite the concept not being novel [9, 10]. Ongoing clinical trials and research are being conducted to advance our understanding of the efficacy and safety of phage therapy in treating various infections [11–13]. An essential aspect of optimizing and refining this therapeutic strategy is understanding the fundamental biological processes at multiple levels.

The multiomics approach is a general methodology in biomedical and life sciences research that combines data from multiple “omics” disciplines to obtain a comprehensive and integrated understanding of biological systems [14, 15]. “Omics” refers to the field of large‐scale investigations of biological molecules. The multiomics approach integrates data from several omics layers, including genomes, transcriptomics, proteomics, and metabolomics, to offer a comprehensive understanding of the functioning and environmental responses of biological systems [16]. Genomics involves the quantitative analysis of an organism’s entire DNA, encompassing both its sequence and structure [17]. Transcriptomics, on the other hand, focuses on the comprehensive collection of RNA transcripts generated by the genome, providing valuable insights into gene expression and control in the context of phage therapy. Analysis of RNA expression, known as transcriptomics, can reveal alterations in gene expression and shed light on phage effects on bacterial regulatory networks, aiding the development of more sophisticated phage formulations [18]. In proteomics, researchers undertake the comprehensive analysis of proteins produced by an organism, exploring their functions, interactions, and alterations [19]. Proteomics enables a comprehensive examination of all proteins in an organism, providing valuable insights into protein expression and alterations. Understanding these protein dynamics can help advance phage therapeutics with improved selectivity and effectiveness. Molecular metabolomics involves examining metabolic profiles to understand the biochemical alterations and metabolic conditions in bacteria when exposed to phage therapy [20].

Through the integration of diverse omics data, comprehensive knowledge on the strategies through which genetic molecules manifest their functional outcomes at the molecular, cellular, and systemic scales can be derived [21, 22]. This holistic perspective clarifies intricate biological processes, disease mechanisms, and individual genetic variations in relation to food, health, and disease. An investigation into phage resistance in the food industry using multiomics analysis revealed that the development of phage resistance has a pleiotropic effect on several cellular processes and metabolism [23]. This analysis offers a more comprehensive evaluation and understanding of the impact of phage candidate development on resistance [23]. Phages have been used in clinical settings, especially in Eastern Europe, for a considerable period [24]. In its early years, phage therapy was hindered by a lack of understanding of phage biology. Additionally, current phage therapy faces challenges, including safety and regulatory issues, across various regions, including the United States and Western Europe [25]. This review highlights the innovative applications of metabolomics, transcriptomics, and proteomics in enhancing the effectiveness of phage therapy. By integrating data from metabolomics, transcriptomics, and proteomics, this review is aimed at providing a comprehensive understanding of how various omics methodologies can enhance the effectiveness of phage therapy. Utilizing this holistic approach can lead to more effective phage designs, better predictions of treatment effectiveness, and ultimately, more successful applications of phage therapy in combating bacterial diseases.

1.1. Method for Selection of Literature

Data was retrieved from scientific databases such as Google Scholar, PubMed, Scopus, ScienceDirect, and Web of Science. Keywords or search strings used in the search include phage therapy, multi‐omics, transcriptomics, metabolomics, proteomics, genomics, antibiotics, bacteria–phage interactions, omics, and phage. These keywords were used alone and in combination to find relevant material from electronic databases. To be considered for inclusion in the review, peer‐reviewed studies, official reports, and policy documents relevant to infection prevention and AMR included and identified information about the application of phage therapy and omics bioinformatics tools. To ensure currency and relevance, results were filtered by publication date (2015–2025), language (English only), and access type (open‐access articles). Articles that did not meet these criteria were excluded.

2. Phage Therapy: An Overview

Phage therapy, the use of bacteriophages for treating bacterial infections, has gained renewed attention recently as a potential solution to the growing problem of antibiotic resistance [26, 27]. Phage therapy, a notion initially developed in the early 20th century, lost popularity with the introduction of antibiotics [28]. Bacteriophages provide a natural alternative to current antibiotics [29]. The prevalence of multidrug‐resistant (MDR) bacteria has attained an incongruous level worldwide and threatens global public health as a silent pandemic, thus leading to a revival in phage research and its therapeutic applications [3].

Phages function by binding to unique receptors on the surface of bacterial cells, introducing their genetic material into the host, and commandeering the bacterial machinery to generate new virions [30]. This process ultimately leads to the lysis or destruction of the bacterial host cell, thereby liberating new phages that can also infect additional bacterial cells. Phage therapy is no longer a futuristic medical concept but rather a real, life‐saving intervention for patients suffering from severe MDR bacterial infections [27, 31, 32]. The specificity of phages to bacterial hosts is both a benefit and a constraint to phage therapy [33]. Although it enables precise treatment with little interference with the body’s indigenous microbiota, it limits the potential to infect multiple strains that may be present in each disease situation [34]. Moreover, the need to better understand phage–bacteria interactions is also critical to ensure the success of phage therapy applications [5, 35]. Table 1 provides an overview of some documented phage applications.

Table 1.

Recent case studies of the application of phages.

Clinical application
Causal agent Infection caused Route of administration/methodology Outcome/result Reference
  
XDR Acinetobacter baumannii and multidrug‐resistant (MDR) Klebsiella pneumoniae Bone infection caused by trauma Intravenous Quick tissue repair and elimination of pathogens after 35 weeks [36]
MDR Pseudomonas aeruginosa Cystic fibrosis (CF) Intravenous No more episodes of CF flare‐ups after about 14 weeks [37]
Penicillin‐resistant Staphylococcus aureus Osteomyelitis in diabetic foot ulcers Soft tissue Full recovery following a 3‐year period [38]
MDR Pseudomonas aeruginosa Septicaemia Intravenous Although the patient’s blood was disinfected by phage therapy, the administration of the medication had to be stopped due to escalating heart failure and allergy risk [39]
MDR Pseudomonas aeruginosa and Staphylococcus aureus Hip infection Soft tissue No clinical indications of illness after one and a half years [40]
MDR Acinetobacter baumannii Necrotizing pancreatitis Intravenous and soft tissue Recovery from infection and restoration of health [41]
Staphylococcus aureus Long‐term skin illness Topical application of phage preparation/oral Decrease in the number of bacteria and improved clinical state [42]
Colistin‐only‐sensitive Pseudomonas aeruginosa Bacterial blood infection and knee infection Intravenous and soft tissue Septicaemia cleared; however, the pathogen was still present in the wound [43]
MDR Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, Klebsiella aerogenes, Pseudomonas aeruginosa, and Enterococcus faecium Various infections, including bacteremia, osteomyelitis, joint, urinary tract, and respiratory infections Several routes, including intravenous, topical, intra‐articular, intraoperative 66% of patients showed favorable responses; 42% achieved bacterial eradication; and no major adverse reactions were reported [44]
Staphylococcus aureus Diabetic foot infection Topical Anti‐S. aureus phage therapy was administered to 10 high‐risk amputation patients. The treatment was effective in 9 patients; 1 patient did not respond [45]
Klebsiella pneumoniae Sternal wound infection (mediastinitis) following aortic arch surgery Intravenous The patient remains infection‐free after 2 years of follow‐up intravenous and local administration [46]
Staphylococcus epidermidis Chronic orthopedic infection Intraoperative Phage therapy administered with a successful outcome. The patient remained infection‐free at the 6‐month follow‐up [47]
  
Application in foods
Phage Product tested Methodology Outcome Reference
  
phiEco1, phiEco2, phiEco3, phiEco5, phiEco6, and phiS1 Oyster A 24‐h‐old bacterial culture was added to the oysters and incubated for 1 h at 37°C to allow attachment. The oyster meat was then incubated appropriately after the addition of the phage suspension Phages were still able to lower the E. coli concentration on the oyster meat [48]
Cocktail composed of phages DT1–DT6 Milk and meat A phage cocktail was applied to samples under various circumstances At both 24°C and 37°C, the phage cocktail effectively reduced the E. coli burden in the food products tested [49]
E. coli‐specific phage Lettuce, cucumber, and carrot The various veggies were submerged in E. coli suspensions for 30 min, and then, they were kept at 37°C for 24 h. After that, the veggies received successive treatments from phages and cold nitrogen plasma After 9 days of the sequential treatment, no viable bacteria were found. On the 3rd day, cell viability had decreased to 1.21 log10 CFU/g. The temperature difference had no bearing on the outcomes [50]
Phage OSY‐SP Green pepper and spinach E. coli was spot‐injected into both matrices (pepper and spinach). To optimize the phage application process, the products were rinsed with phage lysate and phages suspended in PBS prior to storage Cell loss was noted under chilled storage circumstances. In both fresh produce tests, the phage rinse treatment was effective [51]
FAHEc1 UHT milk; ready‐to‐eat meat; raw beef Phages and E. coli O157:H7 were added to UHT milk for inoculation. To mimic the phage application immediately prior to slathering in carcasses, raw beef was inoculated at 37°C UV‐treated phages (UVPs) reduced the number of colony‐forming units (CFUs) by 2–2.5 log10 in milk and 1.75–2.5 log10 in raw beef [52]

Abbreviations: MDR, multidrug‐resistant; XDR, extensively drug‐resistant.

3. Multiomics in Phage Therapy

To gain a comprehensive understanding of biological systems, the multiomics approach combines data from various “omics” disciplines, such as genomics, transcriptomics, proteomics, and metabolomics [53]. In the field of phage therapy, omics techniques are particularly beneficial as they allow researchers to explore the complex interactions between bacteriophages and their bacterial hosts at multiple molecular levels [23, 54]. Examining these interactions from different omics perspectives offers opportunities to gain valuable insights into the effects of phages on bacterial gene expression, protein synthesis, and metabolic pathways [55]. This knowledge is crucial for optimizing phage therapy, as it helps in identifying key weaknesses in bacteria that phages can exploit. Moreover, the utilization of a multiomics methodology could enhance the development of individualized phage therapeutics tailored to the specific characteristics of a disease, potentially improving therapeutic outcomes [56–58]. Therefore, the integration of multiomics data holds great promise in enhancing the efficacy and precision of phage therapy.

3.1. The Value of Multiomics in Phage Therapy

The dynamic interactions between phages and their bacterial hosts make phage therapy a complex process, despite its potential [5, 26]. Conventional approaches, which focus on discrete elements like gene expression or protein synthesis, may provide only a partial understanding of these interactions. In contrast, bacteria respond to phage infection simultaneously on multiple levels, including genetic, transcriptomic, proteomic, and metabolic responses. The multiomics approach, which integrates these different layers, enables a more comprehensive understanding of how phages operate within bacterial cells and how bacteria can develop resistance [35, 59]. For instance, the translation of stress reactions by bacteria into functional proteins can be uncovered by combining transcriptomic data, which tracks changes in gene expression, with proteomic data, which shows alterations in protein quantity and modification [60]. On the other hand, metabolomic data can illustrate how these proteins impact metabolic pathways, aiding the bacterium in survival, or how the phage disrupts these pathways, leading to bacterial lysis [61]. Omics technologies have therefore been successfully employed to accurately characterize bacteriophages and their genes and proteins important for interaction with bacterial hosts [62].

3.2. Benefits of Integrating Omics Data

To understand the molecular mechanisms by which phages hijack their bacterial hosts, omics technologies have the potential to provide novel insights into the organization of transcriptional and translational events that occur during the infection process [63]. Integrating multiomics datasets enables the identification of key points in bacterial metabolism or regulatory networks that phages exploit [22]. This data is essential for developing more efficient phage‐based treatment agents that can simultaneously target several pathways with a significant decrease in bacterial resistance [23]. More so, multiomics methodologies allow for the development of highly sensitive pathogen‐targeted phage‐based treatments, resulting in more efficient biocontrol or therapeutic procedures [64, 65]. The potential of multiomics approaches to provide information on gene expression, uncover the appropriate quantities and conformations of proteins, and elucidate the impact of these proteins on the metabolic functions within the cell makes multiomics protocols a unique strategy in obtaining insights into the mechanisms underlying phage–bacteria interactions [22, 66].

3.3. Challenges of Multiomics Approaches and Future Perspectives

Notwithstanding its potential, the multiomics method presents some difficulties as the integration of extensive and intricate datasets from many omics disciplines requires sophisticated computational tools and specialized knowledge in bioinformatics [67, 68]. Furthermore, the analysis of multiomics data is complex, since alterations documented at one molecular level may not exhibit a direct correlation with those at another level. As such, advancements in computational approaches and machine learning algorithms have the potential to enhance the capacity to combine and interpret multiomics data, hence becoming a more reliable tool in phage therapy research [69–71]. Additionally, the multiomics approach provides a comprehensive framework for understanding and enhancing phage therapy. The integration of data from metabolomics, transcriptomics, proteomics, and other omics disciplines enables researchers to create more efficient, focused, and individualized phage therapies, potentially transforming the battle against antibiotic‐resistant bacteria [65].

4. Metabolomics in Phage Therapy

Understanding the biochemical alterations brought about by phage infection can be achieved with metabolomics, the study of the complete set of tiny molecules or metabolites within a biological system [72, 73]. The concentrations of metabolites, as byproducts of cellular activities, provide a real‐time representation of a cell’s physiological state. The application of metabolomics in phage therapy significantly enhances our understanding of the interference of phages with bacterial metabolism, as well as the mechanisms by which bacteria develop resistance to these biocontrol agents [74].

4.1. Analytical Approaches in Metabolomics

Metabolomic analysis commonly employs mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy methods to accurately measure and categorize metabolites in a sample [75, 76]. These methodologies can be used to examine the metabolite profiles of bacteria before and during phage infection, thereby uncovering alterations in metabolic pathways that may be crucial for the survival or death of the bacterial cell [77, 78].

Both targeted and untargeted metabolomics offer unique benefits in phage research. Targeted metabolomics emphasizes specific metabolites, ensuring elevated sensitivity, precision, and dependable quantitative results [79]. This is particularly advantageous for examining specific hypotheses about host–phage interactions, such as nucleotide pools during phage replication [80, 81]. Nevertheless, its scope is constrained, and it may overlook unforeseen or innovative metabolic alterations triggered by infection.

In contrast, untargeted metabolomics encompasses a wide array of metabolites, facilitating the identification of previously unrecognized pathways that are modified during phage infection [81]. This holds significant importance considering the intricate nature and swift metabolic reorganization induced by phages. The compromise involves reduced quantitative accuracy, increased complexity in data analysis, and possible difficulties in metabolite identification [79, 82].

Phage infection frequently triggers rapid, transient alterations in metabolite flux, making quenching essential to maintain an accurate representation of intracellular conditions [83]. Efficient quenching techniques, such as swift cooling with cold solvents or filtration followed by freezing, promptly halt enzymatic activity within moments, thereby averting metabolic alterations postsampling [84]. In the absence of adequate quenching, quantified metabolite concentrations may fail to accurately reflect in vivo conditions, thereby compromising the integrity of both targeted and untargeted analyses.

4.2. Role and Impact of Metabolomics in Phage–Bacteria Interactions

Phage infection induces substantial metabolic changes in the bacterial cell, resulting in the production of additional virions. These changes can encompass modifications in energy generation, nucleotide synthesis, and membrane lipid metabolism, all of which are essential for the propagation of DNA viruses [85]. A few studies have demonstrated that phage infection results in an augmentation in the synthesis of specific nucleotides and amino acids that are crucial for the formation of phage DNA and proteins [83, 86]. By identifying these important metabolic alterations, metabolomics can provide prospective targets for improving phage therapy [87]. Phages that exploit specific metabolic pathways during infection of the host cell and result in bacterial lysis may be very useful in devising treatments that further diminish these pathways, hence increasing the vulnerability of the bacterial cell to the phage. In general, metabolomics plays a crucial role in phage therapy by providing in‐depth knowledge that enables the development of methods to enhance the specific selection of phages, techniques to increase the susceptibility of bacteria to phages, and a potential decrease in bacterial resistance to phages [62]. As the field of metabolomics advances, its integration with other omics methodologies is expected to yield more advanced and efficient phage‐based therapies.

4.3. Case Studies in Metabolomics and Phage Therapy

The propagation of phages depends on bacterial metabolism; thus, several studies have reported the significance of metabolomics in enhancing phage therapy [88, 89]. A pertinent example is the examination of Pseudomonas aeruginosa, a prevalent microorganism associated with diseases acquired in healthcare facilities [90]. Analysis of the metabolome of P. aeruginosa after phage infection showed notable alterations in its core carbon metabolism, particularly in the tricarboxylic acid (TCA) cycle and glycolytic pathways [90]. Through the analysis of these metabolic changes, certain metabolic obstacles that may be utilized to improve the effectiveness of phages were successfully detected. A further illustration is the utilization of metabolomics to comprehend the processes of phage resistance in bacteria. The identification of metabolic alterations that provide resistance to phages can offer valuable insights into strategies to counteract or prevent the development of such resistance [91–93].

5. Transcriptomics in Phage Therapy

The examination of RNA transcripts produced by the genome, referred to as transcriptomics, is crucial for understanding the complex changes in gene expression that occur during phage infection of bacterial cells [85]. Through the examination of the transcriptome, it is possible to identify the specific genes that are activated or deactivated in response to phage attack [94]. This analysis provides a valuable understanding of bacterial defense mechanisms and the strategies employed by phages to hijack the cellular machinery of their host.

5.1. Techniques and Methodologies in Transcriptomics

For transcriptomic investigations, high‐throughput sequencing methods such as RNA‐Seq are used to comprehensively profile all RNA molecules in a cell, including mRNA, rRNA, tRNA, and noncoding RNAs [95, 96]. The aforementioned methodology facilitates the identification of alterations in gene expression during several phases of phage infection, encompassing the first adherence of the phage to the bacterial cell and subsequent cell lysis [62]. RNA‐Seq provides a detailed assessment of the transcriptome, including precise measurements of gene expression levels and uncovering alternative splicing processes, posttranscriptional changes, and the presence of hitherto unidentified genes [97, 98]. The provided insights are of great value for analyzing the intricate regulatory networks that control the interactions between phages and bacteria.

5.2. Role and Significance of Transcriptomics in Understanding Phage–Bacteria Interactions

Phage infection induces significant alterations in the transcriptome composition of the bacterial host. The field of transcriptomics offers a thorough perspective on the alterations in gene expression that take place during phage infection, therefore providing insight into the molecular mechanisms utilized by both phages and their bacterial hosts [99]. During the initial stages of infection, phages frequently stimulate the production of their own genes while concurrently deactivating the host’s transcriptional control system. An example is the transcriptomic study of Escherichia coli infected by T4 phage, which documented a swift decrease in host genes related to DNA replication and repair, as well as an increase in phage genes essential for DNA packaging and phage assembly [63]. This subversion enables phages to give priority to the synthesis of viral components required for the formation of new virions [18] and to enhance phage therapy methods, such as modifying phages to bypass bacterial defense mechanisms or combining phages with adjuvants that selectively block bacterial pathways.

Transcriptomics can reveal the bacterial stress responses elicited by phage infection, including the activation of SOS responses, a regular regulatory network employed by bacteria to repair DNA damage [100, 101]. A proper understanding of these reactions is crucial for developing effective strategies to combat bacterial resistance to phages. Integrating transcriptome data with other omics datasets, such as proteomics and metabolomics, allows for a comprehensive understanding of the phage–host interaction, thereby facilitating the development of more efficient and tailored phage‐based treatments [54].

5.3. Case Studies in Transcriptomics and Phage Therapy

Several studies have applied transcriptomics to phage therapy, and a classic example is the investigation of Vibrio cholerae, the causative agent of cholera, during infection with a lytic phage, denoted International Centre for Diarrheal Disease Research, Bangladesh cholera phage 1 (ICP1 phage) [102–104]. Transcriptomic studies have demonstrated that this phage commandeers the host’s RNA polymerase, diverting its activity to transcribe genes specific to the phage while suppressing the expression of host‐relevant genes [102]. This provided a detailed understanding of how the ICP1 phage effectively regulates the bacterial transcriptional apparatus to guarantee its successful spread within the host cell, as well as its contribution to the evolution of epidemic V. cholerae.

Additionally, transcriptomic profiling of P. aeruginosa during phage infection revealed the activation of genes associated with oxidative stress and DNA repair, indicating the host cell’s efforts to mitigate damage caused by phages [105, 106]. These, therefore, indicate that phage therapy can be optimized to increase bacterial sensitivity to phage attack by carefully targeting these stress response pathways [35].

6. Proteomics in Phage Therapy

A crucial tool in the field of protein‐level interactions between bacteriophages and their bacterial hosts is proteomics, which is the comprehensive study of proteins within a biological system [107]. Analyzing changes in the proteome during phage infection provides a direct understanding of the mechanisms through which phages affect bacterial cells and how bacterial hosts react to these attacks, since proteins are the primary functional molecules carrying out most cellular processes [63, 108].

6.1. Techniques and Methodologies in Proteomics

Proteomic analysis commonly employs methods such as MS to detect and quantify proteins in complex mixtures and two‐dimensional gel electrophoresis (2D‐GE) to separate proteins based on their respective isoelectric points and molecular weights [109]. Progress in MS, including tandem MS/MS and label‐free quantification techniques, has greatly enhanced the sensitivity and precision of protein identification [110]. This has enabled scientists to analyze hundreds of proteins in a single operation. These methods enable the detection of phage‐encoded proteins produced during infection, as well as bacterial proteins whose expression may be altered during phage invasion [111]. Careful analysis of the proteome profiles of bacterial cells infected with phages and those that are not infected enables the mapping of protein‐level alterations that occur during the various phases of phage infection.

6.2. Role of Proteomics in Understanding Phage–Bacteria Interactions

The field of proteomics offers comprehensive data on the posttranslational modifications (PTMs) of proteins, including phosphorylation, acetylation, and ubiquitination, which have the potential to greatly impact protein function and stability [112]. PTMs are frequently very crucial in controlling the function of both bacterial and phage proteins during phage infection [113]. For instance, certain phages encode proteins that selectively alter bacterial proteins to interfere with regular cellular functions or to avoid bacterial defenses [114].

Evidence from proteomic investigations has shown that phage infection can cause the targeted breakdown of bacterial proteins, inhibition of bacterial defense mechanisms, and alteration of host cellular pathways to promote viral reproduction [86, 74]. An investigation of Staphylococcus aureus infected by the phage P68, using proteome analysis, revealed the breakdown of host proteins responsible for DNA repair and metabolic pathways [115]. The degradation significantly reduced the bacterial host cell’s ability to recover from the damage caused by the phage [115].

6.3. Case Studies in Proteomics and Phage Therapy

Several studies have assessed the impact of proteomic investigations on phage–host interaction that may be useful in the development of more successful therapeutic applications for phages [63, 116, 117]. An exemplary demonstration of proteomics in phage therapy is the study of Listeria monocytogenes infected by the A511 phage. The study accurately detected the expression of phage proteins that inhibit bacterial cell wall and protein synthesis and efficiently trigger bacterial lysis. These findings suggest potential focal points for either developing phages with enhanced lytic capabilities or improving their bactericidal action [116]. In a separate investigation, proteomics was used to detect bacterial proteins that are either reduced in expression due to phage hijacking or increased in expression to promote defense by E. coli infected with T4 phage. The investigation identified crucial proteins involved in maintaining the cell membrane’s integrity and responding to stress, thereby offering insights into the potential exploitation of phage therapy [63].

6.4. Impact of Proteomic Data on Phage Therapy

In addition to identifying potential indicators of bacterial sensitivity to phages, proteomics provides a more comprehensive understanding of how phages regulate bacterial cells. By quantifying the proteome of bacteria during phage infection, it is possible to pinpoint crucial proteins or pathways that, when interfered with by phages, lead to bacterial death [118]. This knowledge can be applied to develop more efficient phage therapies, such as combining phages with drugs that target bacterial proteins or modifying phages to directly transport harmful proteins to bacterial cells [119].

Furthermore, combining proteomics with other omics techniques can provide a better understanding of how phages and hosts interact, thus leading to the discovery of the complex networks that control bacterial survival and phage effectiveness [70]. Future advancement of personalized phage therapeutics, tailored to the distinct proteomic and metabolic characteristics of bacterial pathogens in individual patients, is anticipated to be greatly impacted by this multiomics methodology [66, 67].

7. Integration of Multiomics Data in Phage Therapy

Multiomics‐based data on bacteria during phage infection provide a system‐level understanding of how phages subvert the cellular machinery of their target hosts [120]. The integration of knowledge from transcriptomics, proteomics, metabolomics, and other omics fields offers a state‐of‐the‐art approach to phage therapy and a comprehensive understanding of phage–host interactions [121]. This approach also affords the opportunity to overcome the limitations of single‐omics studies, which can only provide a limited understanding of the numerous biological pathways involved in phage infection.

7.1. Importance of Multiomics Integration

The molecular alterations that occur within bacterial cells during phage infection are analyzed from a different angle by each field of omics. Proteomics reveals changes in protein levels and modifications, metabolomics highlights changes in metabolic pathways, and transcriptomics explains variations in gene expression. These facts are related, though, since the genes are translated into RNA, RNA is translated into proteins, and proteins accelerate metabolic processes [122], which is the fundamental view [123] (Figure 1a). Researchers may create intricate models of how phages affect bacterial cells and how bacteria respond by combining data from several sources across multiple levels (Figure 1b).

Figure 1.

Figure 1

(a) Overview of multiomics approaches. (b) Diagrammatic illustration of strategies for the integration of multiomics data. Vertical integration connects the genomic, transcriptomic, and proteomic layers within a unified framework. (B) Horizontal integration involves comparing omics data across strains or phages. (C) The synthesis of RNA‐Seq and proteomics data demonstrates the processes of normalization, feature matching, scaling, and multivariate analysis to produce outputs that hold biological significance.

For example, correlations between transcriptome alterations and related proteomic shifts, such as the upregulation of RNA transcripts resulting in higher protein production, can be identified using a multiomics method [124]. In a similar vein, combining metabolomic data can shed light on how these modifications to the protein impact bacterial metabolism, offering a more comprehensive understanding of the physiological effects of phage infection [125].

7.2. The Role of Multiomics Integration in Precision Phage Therapy Development

The integration of multiomics data has significantly advanced the development of phage therapy [23, 54]. This technology has enabled the identification of essential bacterial processes that phages target, thereby improving the development of phages that target multiple pathways simultaneously, thus reducing the likelihood of bacterial resistance development. Furthermore, the use of multiomics approaches has facilitated the development of more tailored phage therapies, in which phages are selected or altered based on the distinct molecular features of the pathogen in a particular patient [126].

Moreover, the identification of biomarkers that predict the efficacy of phage therapy relies on the integration of several omics techniques [126]. Researchers can develop diagnostic techniques to choose the most effective phages for treating infections by identifying well‐defined metabolic or proteomic pathways associated with successful phage infection [77, 127].

7.3. Applications of Multiomics in Phage Therapy

Literature has a few omics‐acclaimed approaches in phage research. Table 2 provides an overview of these approaches, which include their potential as biocontrol agents, protein profiling, and changes in phage–host interactions, such as transcriptional responses and active gene profiling.

Table 2.

Overview of multiomics approach in phage research.

Phage Host Omics technique Application Major finding Reference
Phage cocktail P. aeruginosa Metabolomics Modifications in the metabolic functioning of the host during infection Rapid, dynamic metabolic shift in the host [90]
Dp‐1 and Cp‐1 S. pneumoniae Proteomics Phage–host interaction System‐level (highly specific, nonrandom protein–protein interactions) view of phage–host [128]
PaP3 P. aeruginosa Transcriptomics Phage–host interaction Dynamic, bidirectional interaction between the phage and the host [129]
vB_BpuM_BpSp Bacillus Proteomics Specific protein analysis Identified the actual structural protein composition of a jumbo phage, including novel functional proteins [130]
MC1061 (ϕ24B) E. coli Transcriptomics Modified host function upon phage infection Revealed functional consequences of lysogeny at the regulatory level [131]
ΦMSP S. aureus Proteomics Protein analysis Identified the structural protein composition of lytic Staphylococcus aureus phages [132]
T5‐like phage E. coli O157:H7 Genomics, proteomics Biocontrol Validated functional expression [133]
ϕTMA Thermus thermophilus Genomics, proteomics Genome and protein profiling Validated genome annotations and assigned functional relevance [134]
ΦCP39O and ΦCP26F Clostridium perfringes Genomics, proteomics Genome and protein profiling Genome annotation and prediction [135]
MS2 E. coli Metabolomics Phage–host interaction Functional metabolic outcomes of infection [136]

The integration of transcriptomic and proteomic data enables the identification of critical bacterial processes required for survival during phage infection, thereby allowing the development of phages that preferentially target these pathways with enhanced efficiency and potentially result in faster and more effective bacterial lysis [137]. For example, when transcriptomic analyses reveal the upregulation of stress response genes and proteomic data confirm the presence of corresponding stress‐related proteins, phages can be designed or selected to deliberately interfere with these proteins, consequently compromising bacterial defense mechanisms and enhancing phage efficacy.

Personalized phage therapy has become increasingly feasible through the integration of multiple omics approaches, enabling treatments to be tailored to the unique molecular profiles of bacterial infections in individual patients [138]. By analyzing transcriptomic, proteomic, and metabolomic data from a specific bacterial strain, researchers can design or select phages that are most likely to be effective against it. This customized strategy is crucial for treating infections caused by MDR pathogens, where conventional phage cocktails may be ineffective [139].

Furthermore, integrating data from multiple omics platforms enables the identification of biomarkers that can predict the efficacy of phage therapy. These biomarkers may include specific metabolites, proteins, or gene expression profiles that are associated with bacterial susceptibility to phage infection [54]. For instance, if a particular metabolic pathway is consistently disrupted in bacterial strains that are susceptible to a given phage, the metabolites associated with it could serve as biomarkers to guide phage selection in clinical applications.

Multiomics approaches are also essential for elucidating the mechanisms underlying bacterial resistance to phages [140]. By examining transcriptomic and proteomic changes in bacterial populations that survive phage infection, researchers can identify the genetic and protein‐level adaptations that confer resistance to phage infection. This knowledge can then be leveraged to develop phages capable of circumventing these resistance mechanisms, either by directly targeting newly acquired pathways or by combining phage therapy with adjunct treatments that inhibit the emergence of resistance [23].

7.4. Challenges and Prospects

Although multiomics data integration in phage therapy has enormous potential, it also presents distinct problems [141, 142]. Table 3 highlights some methodological challenges in leading bioinformatics tools/pipelines for multiomics integration in microbial systems.

Table 3.

Summary of the leading bioinformatics tools for multiomics integration in microbial systems.

Tool/pipeline Omics integrated Key features Strengths Limitations Reference
mixOmics Genomics, transcriptomics, proteomics, metabolomics Multivariate approaches (PLS, sPLS, DIABLO) for integration and feature selection Strong for biomarker discovery; powerful visualization; widely used Requires R expertise; computationally demanding for large datasets [143, 144]
MOFA+ Genomics, transcriptomics, epigenomics, proteomics Unsupervised factor analysis identifying shared and dataset‐specific variation Handles missing data, interpretable latent factors, and scalability Requires statistical knowledge; less intuitive for beginners [143, 145]
PaintOmics Transcriptomics, metabolomics (with genomics support) Pathway‐based integration and visualization using KEGG maps User‐friendly; strong biological interpretation via pathways Limited for deep statistical integration; dependent on pathway databases [146]
iClusterPlus Genomics, transcriptomics, epigenomics Joint latent variable model for clustering multiomics data Good for identifying strain/population structure Limited metabolomics support; less scalable [145]
Cytoscape (with plugins) Flexible (multiomics) Network‐based integration and visualization Excellent for interaction networks; highly customizable Requires plugins for full integration; less automated [147, 148]
MetaboAnalyst Metabolomics + transcriptomics (limited multiomics) Statistical analysis, pathway mapping, and data integration tools Easy to use; strong metabolomics focus Limited depth for full multiomics integration [146, 149]

Also, the vast amount and intricate nature of data necessitate advanced bioinformatics tools and specialized knowledge in data analysis. Furthermore, the task of evaluating the connections among several omics layers can be challenging, since alterations in one layer may not always reflect directly on alterations in another [142, 150]. For example, a gene can exhibit high expression levels, as demonstrated by transcriptomics. However, its associated protein may undergo posttranslational changes that change its function, a specific piece of information that can only be detected using proteomics approaches. Also, observed discrepancies between mRNA and protein levels often suggest regulatory mechanisms at the translational level. Translatomics, such as Ribo‐seq, elucidates transcripts undergoing active translation, whereas phage‐encoded small RNAs (sRNAs) can modify mRNA stability or translation efficiency [151–154]. The interplay among these layers elucidates the reasons for the divergence between transcript and protein data, underscoring the significance of “missing links” essential for comprehending phage–host interactions in the context of multiomics studies [155, 156].

Moreover, comparing different omics metrics for the same biological subsystem poses challenges in the context of multiomics data, complicating the communication of the alterations occurring within a biological system [157].

Continued progress in computational biology, machine learning, and systems biology is anticipated to further enhance the integration and analytical capabilities of multiomics data. These technologies will facilitate the construction of more precise models of phage–host interactions, hence facilitating the advancement of next‐generation phage therapies that exhibit enhanced efficacy, specificity, and individualization [53, 158].

Furthermore, with the ongoing reduction in the expenses associated with omics technologies, it is anticipated that multiomics methods will become more affordable, therefore enabling their regular utilization in phage treatment research and clinical applications [159]. Undoubtedly, this will result in a more profound comprehension of the dynamics between phages and bacteria, thus creating novel opportunities to address antibiotic‐resistant diseases.

Ultimately, the incorporation of multi‐omics data is crucial for fully harnessing the capabilities of phage therapy [160, 161]. Through a thorough analysis of the molecular interactions between phages and bacteria, this method has the potential to facilitate the creation of more efficient, focused, and individualized therapies, thus improving the clinical efficacy of phage therapy [71, 162].

8. Conclusion and Future Perspective

Molecular metabolomics provides valuable insights into the metabolic alterations that occur during phage infection, thereby uncovering potential metabolic susceptibilities in bacteria. Transcriptomics reveals the alterations in gene expression that phages cause to undermine bacterial defenses, providing opportunities to improve the effectiveness of phage toxins. In turn, proteomics reveals the protein‐level interactions and PTMs that are crucial for the replication of phages and the response of bacteria. The integration of multiomics methodologies, including those mentioned above, represents a major breakthrough in the field of phage therapy. These various omics techniques provide a robust set of tools for the development of more efficient and individualized phage therapeutics. By integrating these various strata of biological data, scientists can gain a comprehensive understanding of the complex interactions between bacteriophages and their bacterial hosts. It is essential to adopt a comprehensive viewpoint in order to maximize phage therapy, especially considering the increasing phenomenon of antibiotic resistance.

In the future, the ongoing progress in computational tools and the declining expenses of omics technologies are anticipated to enhance the accessibility of multiomics techniques. These developments are expected to lead to further advancements in phage therapy, providing renewed optimism in combating antibiotic‐resistant diseases and making a valuable contribution to the broader field of precision medicine.

Author Contributions

Conceptualization: D.J.A. and C.N.A. Methodology: D.J.A. Validation: D.J.A. and C.N.A. Writing—original draft preparation: D.J.A. Writing—review and editing: D.J.A. and C.N.A. Supervision: C.N.A.

Funding

No funding was received for this manuscript.

Disclosure

All authors have read and agreed to the published version of the manuscript.

Ethics Statement

The authors have nothing to report.

Consent

The authors have nothing to report.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

The authors wish to thank the North‐West University, Mafikeng, South Africa, and the University of Mpumalanga, Mbombela, South Africa.

Ajose, Daniel Jesuwenu , Ateba, Collins Njie , Multiomics Approaches for Bacteriophage‐Based Biocontrol Applications: A Review of Metabolomics, Transcriptomics, and Proteomics, BioMed Research International, 2026, 8304153, 17 pages, 2026. 10.1155/bmri/8304153

Academic Editor: Poorani Gurumallesh Prabu

Contributor Information

Daniel Jesuwenu Ajose, Email: ajosedj@yahoo.com.

Collins Njie Ateba, Email: collins.ateba@ump.ac.za.

Poorani Gurumallesh Prabu, Email: pgurumalle@wiley.com.

Data Availability Statement

Data sharing is not applicable to this article, as no datasets were generated or analyzed during the current study.

References

  • 1. Ajose D. J., Adekanmbi A. O., Kamaruzzaman N. F., Ateba C. N., and Saeed S. I., Combating Antibiotic Resistance in a One Health Context: A Plethora of Frontiers, One Health Outlook. (2024) 6, no. 1, 10.1186/s42522-024-00115-7, 39487542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Alrafaie A., Harnessing Phages to Tackle Antimicrobial Resistance: A Saudi Arabian Perspective, Frontiers in Cellular and Infection Microbiology. (2025) 15, 1702890, 10.3389/fcimb.2025.1702890, 41355985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Oluwarinde B. O., Ajose D. J., Abolarinwa T. O., Montso P. K., Njom H. A., and Ateba C. N., Molecular Characterization and Safety Properties of Multi Drug-Resistant Escherichia coli O157: H7 Bacteriophages, BMC Microbiology. (2024) 24, no. 1, 10.1186/s12866-024-03691-w, 39695941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Cisek A. A., Dąbrowska I., Gregorczyk K. P., and Wyżewski Z., Phage Therapy in Bacterial Infections Treatment: One Hundred Years After the Discovery of Bacteriophages, Current Microbiology. (2017) 74, no. 2, 277–283, 10.1007/s00284-016-1166-x, 2-s2.0-84997751519, 27896482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Hibstu Z., Belew H., Akelew Y., and Mengist H. M., Phage Therapy: A Different Approach to Fight Bacterial Infections, Biologics: Targets and Therapy. (2022) 16, 173–186, 10.2147/BTT.S381237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Ireland T., The Good Virus: The Amazing Story and Forgotten Promise of the Phage, 2023, WW Norton & Company. [Google Scholar]
  • 7. Chinemerem-Nwobodo D., Ugwu M. C., Oliseloke Anie C., Al-Ouqaili M. T., Chinedu Ikem J., Victor Chigozie U., and Saki M., Antibiotic Resistance: The Challenges and Some Emerging Strategies for Tackling a Global Menace, Journal of Clinical Laboratory Analysis. (2022) 36, no. 9, e24655, 10.1002/jcla.24655, 35949048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Gordillo Altamirano F. L. and Barr J. J., Phage Therapy in the Postantibiotic Era, Clinical Microbiology Reviews. (2019) 32, no. 2, 10–1128, 10.1128/CMR.00066-18, 2-s2.0-85060144465, 30651225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Sohail H. A., Coffey A., Debrowska K., Meyer I. M., Middelboe M., Sohail M., and Clokie M. R. J., Bacteriophages: Emerging Applications in Medicine, Food, and Biotechnology, Phage. (2020) 1, no. 2, 75–82, 10.1089/phage.2020.29004.has, 36147894. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Novak L. and Clase K., Development of Next Generation Phage Applications Using-Omics and Machine Learning, Proceedings of the BIRS Community. (2023) 1, no. 1. [Google Scholar]
  • 11. Wright A., Hawkins C., Änggård E., and Harper D., A Controlled Clinical Trial of a Therapeutic Bacteriophage Preparation in Chronic Otitis due to Antibiotic-Resistant Pseudomonas aeruginosa; a Preliminary Report of Efficacy, Clinical Otolaryngology. (2009) 34, no. 4, 349–357, 10.1111/j.1749-4486.2009.01973.x, 2-s2.0-68349154135, 19673983. [DOI] [PubMed] [Google Scholar]
  • 12. Jault P., Leclerc T., Jennes S., Pirnay J. P., Que Y.-A., Resch G., Rousseau A. F., Ravat F., Carsin H., le Floch R., Schaal J. V., Soler C., Fevre C., Arnaud I., Bretaudeau L., and Gabard J., Efficacy and Tolerability of a Cocktail of Bacteriophages to Treat Burn Wounds Infected by Pseudomonas aeruginosa (PhagoBurn): A Randomised, Controlled, Double-Blind Phase 1/2 Trial, Lancet Infectious Diseases. (2019) 19, no. 1, 35–45, 10.1016/S1473-3099(18)30482-1, 2-s2.0-85058276087, 30292481. [DOI] [PubMed] [Google Scholar]
  • 13. Leitner L., Ujmajuridze A., Chanishvili N., Goderdzishvili M., Chkonia I., Rigvava S., Chkhotua A., Changashvili G., McCallin S., Schneider M. P., Liechti M. D., Mehnert U., Bachmann L. M., Sybesma W., and Kessler T. M., Intravesical Bacteriophages for Treating Urinary Tract Infections in Patients Undergoing Transurethral Resection of the Prostate: A Randomised, Placebo-Controlled, Double-Blind Clinical Trial, Lancet Infectious Diseases. (2021) 21, no. 3, 427–436, 10.1016/S1473-3099(20)30330-3, 32949500. [DOI] [PubMed] [Google Scholar]
  • 14. Subramanian I., Verma S., Kumar S., Jere A., and Anamika K., Multi-Omics Data Integration, Interpretation, and Its Application, Bioinformatics and Biology Insights. (2020) 14, 117793221989905, 10.1177/1177932219899051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Graw S., Chappell K., Washam C. L., Gies A., Bird J., Robeson M. S., and Byrum S. D., Multi-Omics Data Integration Considerations and Study Design for Biological Systems and Disease, Molecular Omics. (2021) 17, no. 2, 170–185, 10.1039/d0mo00041h, 33347526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Beale D. J., Karpe A. V., and Ahmed W., Beyond Metabolomics: A Review of Multi-Omics-Based Approaches, Microbial Metabolomics: Applications in Clinical, Environmental, and Industrial Microbiology, 2016, Springer, 289–312, 10.1007/978-3-319-46326-1_10, 2-s2.0-85007295137. [DOI] [Google Scholar]
  • 17. Verma M., Kulshrestha S., and Puri A., Genome Sequencing, Bioinformatics: Volume I: Data, Sequence Analysis, and Evolution, 2017, Humana Press, 3–33, 10.1007/978-1-4939-6622-6_1, 2-s2.0-85000786885. [DOI] [Google Scholar]
  • 18. Finstrlová A., Mašlaňová I., Blasdel Reuter B. G., Doškař J., Götz F., and Pantůček R., Global Transcriptomic Analysis of Bacteriophage-Host Interactions Between a Kayvirus Therapeutic Phage and Staphylococcus aureus, Microbiology Spectrum. (2022) 10, no. 3, e00123-22, 10.1128/spectrum.00123-22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Aebersold R. and Mann M., Mass-Spectrometric Exploration of Proteome Structure and Function, Nature. (2016) 537, no. 7620, 347–355, 10.1038/nature19949, 2-s2.0-84988517517, 27629641. [DOI] [PubMed] [Google Scholar]
  • 20. Papaianni M., Cuomo P., Fulgione A., Albanese D., Gallo M., Paris D., Motta A., Iannelli D., and Capparelli R., Bacteriophages Promote Metabolic Changes in Bacteria Biofilm, Microorganisms. (2020) 8, no. 4, 10.3390/microorganisms8040480, 32231093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Zierer J., Menni C., Kastenmüller G., and Spector T. D., Integration of ‘Omics’ Data in Aging Research: From Biomarkers to Systems Biology, Aging Cell. (2015) 14, no. 6, 933–944, 10.1111/acel.12386, 2-s2.0-84954396791, 26331998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Wörheide M. A., Krumsiek J., Kastenmüller G., and Arnold M., Multi-Omics Integration in Biomedical Research–A Metabolomics-Centric Review, Analytica Chimica Acta. (2021) 1141, 144–162, 10.1016/j.aca.2020.10.038, 33248648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Martinez-Soto C. E., Development and Encapsulation of a Multi-Receptor Phage Cocktail Against Salmonella for Poultry Food Safety and Multi-Omics Characterization of Phage Resistance, 2024, University of Guelph. [Google Scholar]
  • 24. Abedon S. T., Kuhl S. J., Blasdel B. G., and Kutter E. M., Phage Treatment of Human Infections, Bacteriophage. (2011) 1, no. 2, 66–85, 10.4161/bact.1.2.15845, 22334863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Kutter E. M., Kuhl S. J., and Abedon S. T., Re-Establishing a Place for Phage Therapy in Western Medicine, Future Microbiology. (2015) 10, no. 5, 685–688, 10.2217/fmb.15.28, 2-s2.0-84929742239, 26000644. [DOI] [PubMed] [Google Scholar]
  • 26. Pires D. P., Costa A. R., Pinto G., Meneses L., and Azeredo J., Current Challenges and Future Opportunities of Phage Therapy, FEMS Microbiology Reviews. (2020) 44, no. 6, 684–700, 10.1093/femsre/fuaa017, 32472938. [DOI] [PubMed] [Google Scholar]
  • 27. Hatfull G. F., Dedrick R. M., and Schooley R. T., Phage Therapy for Antibiotic-Resistant Bacterial Infections, Annual Review of Medicine. (2022) 73, no. 1, 197–211, 10.1146/annurev-med-080219-122208. [DOI] [PubMed] [Google Scholar]
  • 28. Adesanya O., Oduselu T., Akin-Ajani O., Adewumi O. M., and Ademowo O. G., An Exegesis of Bacteriophage Therapy: An Emerging Player in the Fight Against Anti-Microbial Resistance, AIMS Microbiology. (2020) 6, no. 3, 204–230, 10.3934/microbiol.2020014, 33134741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Domingo-Calap P. and Delgado-Martínez J., Bacteriophages: Protagonists of a Post-Antibiotic Era, Antibiotics. (2018) 7, no. 3, 10.3390/antibiotics7030066, 2-s2.0-85051079683, 30060506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Azam A. H. and Tanji Y., Bacteriophage-Host Arm Race: An Update on the Mechanism of Phage Resistance in Bacteria and Revenge of the Phage With the Perspective for Phage Therapy, Applied Microbiology and Biotechnology. (2019) 103, no. 5, 2121–2131, 10.1007/s00253-019-09629-x, 2-s2.0-85060696942, 30680434. [DOI] [PubMed] [Google Scholar]
  • 31. Anomaly J., The Future of Phage: Ethical Challenges of Using Phage Therapy to Treat Bacterial Infections, Public Health Ethics. (2020) 13, no. 1, 82–88, 10.1093/phe/phaa003, 32760449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Sawa T., Moriyama K., and Kinoshita M., Current Status of Bacteriophage Therapy for Severe Bacterial Infections, Journal of Intensive Care. (2024) 12, no. 1, 10.1186/s40560-024-00759-7, 39482746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Ross A., Ward S., and Hyman P., More Is Better: Selecting for Broad Host Range Bacteriophages, Frontiers in Microbiology. (2016) 7, 10.3389/fmicb.2016.01352, 2-s2.0-84992741122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Luong T., Salabarria A.-C., and Roach D. R., Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?, Clinical Therapeutics. (2020) 42, no. 9, 1659–1680, 10.1016/j.clinthera.2020.07.014, 32883528. [DOI] [PubMed] [Google Scholar]
  • 35. Oromí-Bosch A., Antani J. D., and Turner P. E., Developing Phage Therapy That Overcomes the Evolution of Bacterial Resistance, Annual Review of Virology.(2023) 10, no. 1, 503–524, 10.1146/annurev-virology-012423-110530, 37268007. [DOI] [PubMed] [Google Scholar]
  • 36. Nir-Paz R., Gelman D., Khouri A., Sisson B. M., Fackler J., Alkalay-Oren S., Khalifa L., Rimon A., Yerushalmy O., Bader R., Amit S., Coppenhagen-Glazer S., Henry M., Quinones J., Malagon F., Biswas B., Moses A. E., Merril G., Schooley R. T., Brownstein M. J., Weil Y. A., and Hazan R., Successful Treatment of Antibiotic-Resistant, Poly-Microbial Bone Infection With Bacteriophages and Antibiotics Combination, Clinical Infectious Diseases. (2019) 69, no. 11, 2015–2018, 10.1093/cid/ciz222, 30869755. [DOI] [PubMed] [Google Scholar]
  • 37. Law N., Logan C., Yung G., Furr C.-L. L., Lehman S. M., Morales S., Rosas F., Gaidamaka A., Bilinsky I., Grint P., Schooley R. T., and Aslam S., Successful Adjunctive Use of Bacteriophage Therapy for Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infection in a Cystic Fibrosis Patient, Infection. (2019) 47, no. 4, 665–668, 10.1007/s15010-019-01319-0, 2-s2.0-85066087398, 31102236. [DOI] [PubMed] [Google Scholar]
  • 38. Fish R., Kutter E., Bryan D., Wheat G., and Kuhl S., Resolving Digital Staphylococcal Osteomyelitis Using Bacteriophage—A Case Report, Antibiotics. (2018) 7, no. 4, 10.3390/antibiotics7040087, 2-s2.0-85055354353, 30279396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Duplessis C., Biswas B., Hanisch B., Perkins M., Henry M., Quinones J., Wolfe D., Estrella L., and Hamilton T., Refractory Pseudomonas Bacteremia in a 2-Year-Old Sterilized by Bacteriophage Therapy, Journal of the Pediatric Infectious Diseases Society. (2018) 7, no. 3, 253–256, 10.1093/jpids/pix056, 2-s2.0-85055677751, 28992111. [DOI] [PubMed] [Google Scholar]
  • 40. Ferry T., Leboucher G., Fevre C., Herry Y., Conrad A., Josse J., Batailler C., Chidiac C., Medina M., Lustig S., and Laurent F., Salvage Debridement, Antibiotics and Implant Retention (“DAIR”) With Local Injection of a Selected Cocktail of Bacteriophages: Is It an Option for an Elderly Patient With Relapsing Staphylococcus aureus Prosthetic-Joint Infection?, Open Forum Infectious Diseases, 2018, Oxford University Press US. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Schooley R., Biswas B., Gill J., Hernandez-Morales A., Lancaster J., Lessor L., Barr J. J., Reed S. L., Rohwer F., Benler S., Segall A. M., Taplitz R., Smith D. M., Kerr K., Kumaraswamy M., Nizet V., Lin L., McCauley M. D., Strathdee S. A., Benson C. A., Pope R. K., Leroux B. M., Picel A. C., Mateczun A. J., Cilwa K. E., Regeimbal J. M., Estrella L. A., Wolfe D. M., Henry M. S., Quinones J., Salka S., Bishop-Lilly K. A., Young R., and Hamilton T., Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails to Treat a Patient With a Disseminated Resistant Acinetobacter baumannii Infection, Antimicrobial Agents and Chemotherapy. (2017) 61, no. 10, 10–1128, 10.1128/AAC.00954-17, 2-s2.0-85029766008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Zhvania P., Hoyle N. S., Nadareishvili L., Nizharadze D., and Kutateladze M., Phage Therapy in a 16-Year-Old Boy With Netherton Syndrome, Frontiers in Medicine. (2017) 4, 10.3389/fmed.2017.00094, 2-s2.0-85032503812, 28717637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Jennes S., Merabishvili M., Soentjens P., Pang K. W., Rose T., Keersebilck E., Soete O., François P. M., Teodorescu S., Verween G., Verbeken G., de Vos D., and Pirnay J. P., Use of Bacteriophages in the Treatment of Colistin-Only-Sensitive Pseudomonas aeruginosa Septicaemia in a Patient With Acute Kidney Injury—A Case Report, Critical Care. (2017) 21, no. 1, 10.1186/s13054-017-1709-y, 2-s2.0-85020212842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Green S. I., Clark J. R., Santos H. H., Weesner K. E., Salazar K. C., Aslam S., Campbell J. W., Doernberg S. B., Blodget E., Morris M. I., Suh G. A., Obeid K., Silveira F. P., Filippov A. A., Whiteson K. L., Trautner B. W., Terwilliger A. L., and Maresso A., A Retrospective, Observational Study of 12 Cases of Expanded-Access Customized Phage Therapy: Production, Characteristics, and Clinical Outcomes, Clinical Infectious Diseases. (2023) 77, no. 8, 1079–1091, 10.1093/cid/ciad335, 37279523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Young M. J., Hall L. M., Merabishvilli M., Pirnay J.-P., Clark J. R., and Jones J. D., Phage Therapy for Diabetic Foot Infection: A Case Series, Clinical Therapeutics. (2023) 45, no. 8, 797–801, 10.1016/j.clinthera.2023.06.009, 37442654. [DOI] [PubMed] [Google Scholar]
  • 46. Hameed I., Ahmed A., Gandhi S., Nassiri N., Steinbacher D. M., and Vallabhajosyula P., Successful Investigational Phage Therapy for Pan-Resistant Bacterial Mediastinitis Following Type II Hybrid Aortic Arch Replacement, Case Reports. (2024) 29, no. 23, 102816, 10.1016/j.jaccas.2024.102816, 39691337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Munteanu D. I., Dunn J., Apjok G., Kintses B., Griselain J., Steurs G., Cochez C., Djebara S., Merabishvili M., Pirnay J. P., Štilec V., Peterka M., Simpson E. A., Downie S., MacInnes A., Nicol G., Clift B., and Jones J. D., Phage Therapy for Orthopaedic Infections: The First Three Cases From the United Kingdom, Antibiotics. (2025) 14, no. 2, 10.3390/antibiotics14020114, 40001358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Le T. S., Southgate P. C., O’Connor W., Poole S., and Kurtbӧke D. I., Bacteriophages as Biological Control Agents of Enteric Bacteria Contaminating Edible Oysters, Current Microbiology. (2018) 75, no. 5, 611–619, 10.1007/s00284-017-1424-6, 2-s2.0-85039853412, 29282504. [DOI] [PubMed] [Google Scholar]
  • 49. Tomat D., Casabonne C., Aquili V., Balagué C., and Quiberoni A., Evaluation of a Novel Cocktail of Six Lytic Bacteriophages Against Shiga Toxin-Producing Escherichia coli in Broth, Milk And Meat, Food Microbiology. (2018) 76, 434–442, 10.1016/j.fm.2018.07.006, 2-s2.0-85053163623, 30166171. [DOI] [PubMed] [Google Scholar]
  • 50. Cui H., Bai M., Yuan L., Surendhiran D., and Lin L., Sequential Effect of Phages and Cold Nitrogen Plasma Against Escherichia coli O157: H7 Biofilms on Different Vegetables, International Journal of Food Microbiology. (2018) 268, 1–9, 10.1016/j.ijfoodmicro.2018.01.004, 2-s2.0-85040012760, 29306732. [DOI] [PubMed] [Google Scholar]
  • 51. Snyder A. B., Perry J. J., and Yousef A. E., Developing and Optimizing Bacteriophage Treatment to Control Enterohemorrhagic Escherichia coli on Fresh Produce, International Journal of Food Microbiology. (2016) 236, 90–97, 10.1016/j.ijfoodmicro.2016.07.023, 2-s2.0-84978819025, 27454784. [DOI] [PubMed] [Google Scholar]
  • 52. Hudson J., Billington C., Premaratne A., and On S. L., Inactivation of Escherichia coli O157: H7 Using Ultraviolet Light-Treated Bacteriophages, Food Science and Technology International. (2016) 22, no. 1, 3–9, 10.1177/1082013214560445, 2-s2.0-84950325312, 25411154. [DOI] [PubMed] [Google Scholar]
  • 53. Reel P. S., Reel S., Pearson E., Trucco E., and Jefferson E., Using Machine Learning Approaches for Multi-Omics Data Analysis: A Review, Biotechnology Advances. (2021) 49, 107739, 10.1016/j.biotechadv.2021.107739. [DOI] [PubMed] [Google Scholar]
  • 54. AlKhazindar M., El-Senousy W. M., and Abuhadema Y., Multi-Omics in Viral Microbiome, Multi-Omics Analysis of the Human Microbiome: From Technology to Clinical Applications, 2024, Springer, 275–294, 10.1007/978-981-97-1844-3_13. [DOI] [Google Scholar]
  • 55. Kaster A.-K. and Sobol M. S., Microbial Single-Cell Omics: The Crux of the Matter, Applied Microbiology and Biotechnology. (2020) 104, no. 19, 8209–8220, 10.1007/s00253-020-10844-0, 32845367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56. Ferry T., Kolenda C., Laurent F., Leboucher G., Merabischvilli M., Djebara S., Gustave C. A., Perpoint T., Barrey C., Pirnay J. P., and Resch G., Personalized Bacteriophage Therapy to Treat Pandrug-Resistant Spinal Pseudomonas aeruginosa Infection, Nature Communications. (2022) 13, no. 1, 10.1038/s41467-022-31837-9, 35869081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Singha B., Rawat B. S., Venkataraman R., Nair T., Rosenn E. H., and Soni V., Gut Microbiome Associated Dysbiosis: Limited Regimens And Expanding Horizons of Phage Therapy, Aspects of Molecular Medicine. (2023) 2, 100029, 10.1016/j.amolm.2023.100029. [DOI] [Google Scholar]
  • 58. Pirnay J.-P., Djebara S., Steurs G., Griselain J., Cochez C., De Soir S., Glonti T., Spiessens A., Vanden Berghe E., Green S., and Wagemans J., Personalized Bacteriophage Therapy Outcomes for 100 Consecutive Cases: A Multicentre, Multinational, Retrospective Observational study, Microbiology.(2024) 9, no. 6, 1434–1453, 10.1038/s41564-024-01705-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Wright R. C., Friman V.-P., Smith M. C., and Brockhurst M. A., Cross-Resistance Is Modular in Bacteria–Phage Interactions, PLoS Biology. (2018) 16, no. 10, e2006057, 10.1371/journal.pbio.2006057, 2-s2.0-85055071363, 30281587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Qiao J., Huang S., Te R., Wang J., Chen L., and Zhang W., Integrated Proteomic and Transcriptomic Analysis Reveals Novel Genes and Regulatory Mechanisms Involved in Salt Stress Responses in Synechocystis sp. PCC 6803, Applied Microbiology and Biotechnology. (2013) 97, no. 18, 8253–8264, 10.1007/s00253-013-5139-8, 2-s2.0-84883560227, 23925534. [DOI] [PubMed] [Google Scholar]
  • 61. Stokes J. M., Lopatkin A. J., Lobritz M. A., and Collins J. J., Bacterial Metabolism and Antibiotic Efficacy, Cell Metabolism. (2019) 30, no. 2, 251–259, 10.1016/j.cmet.2019.06.009, 2-s2.0-85069974238, 31279676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62. Islam M. R., Martinez-Soto C. E., Lin J. T., Khursigara C. M., Barbut S., and Anany H., A Systematic Review From Basics to Omics on Bacteriophage Applications in Poultry Production and Processing, Critical Reviews in Food Science and Nutrition. (2023) 63, no. 18, 3097–3129, 10.1080/10408398.2021.1984200, 34609270. [DOI] [PubMed] [Google Scholar]
  • 63. Wolfram-Schauerte M., Pozhydaieva N., Viering M., Glatter T., and Höfer K., Integrated Omics Reveal Time-Resolved Insights Into T4 Phage Infection of E. coli on Proteome and Transcriptome Levels, Viruses. (2022) 14, no. 11, 10.3390/v14112502, 36423111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Wang Q., Building Personalized Cancer Therapeutics Through Multi-Omics Assays and Bacteriophage-Eukaryotic Cell Interactions, International Journal of Molecular Sciences. (2021) 22, no. 18, 10.3390/ijms22189712, 34575870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65. Espinosa-González A. M., del Carmen B.-F. J., Gómez-Verjan J. C., Rivero-Segura N. A., Castro I. P., Cabrera J. C. R., and Estrella-Parra E. A., Multi-Omics Profiles Are Applicable to Human Diseases and Drug Development, Biotechnology and Drug Development for Targeting Human Diseases. (2024) 9, 1–19, 10.2174/9789815223163124090003. [DOI] [Google Scholar]
  • 66. Chen C., Wang J., Pan D., Wang X., Xu Y., Yan J., Wang L., Yang X., Yang M., and Liu G. P., Applications of Multi-Omics Analysis in Human Diseases, Medical Communications. (2023) 4, no. 4, 10.1002/mco2.315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67. Hasin Y., Seldin M., and Lusis A., Multi-Omics Approaches to Disease, Genome Biology. (2017) 18, no. 1, 1–15, 10.1186/s13059-017-1215-1, 2-s2.0-85018787862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68. Tarazona S., Arzalluz-Luque A., and Conesa A., Undisclosed, Unmet and Neglected Challenges in Multi-Omics Studies, Nature Computational Science. (2021) 1, no. 6, 395–402, 10.1038/s43588-021-00086-z, 38217236. [DOI] [PubMed] [Google Scholar]
  • 69. Molina-Mora J. A. and García F., Molecular Determinants of Antibiotic Resistance in the Costa Rican Pseudomonas aeruginosa AG1 by a Multi-Omics Approach: A Review of 10 Years of Study, Phenomics. (2021) 1, no. 3, 129–142, 10.1007/s43657-021-00016-z, 35233560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70. Corrivetti G., Monaco F., Vignapiano A., Marenna A., Palm K., Fernández-Arroyo S., Frigola-Capell E., Leen V., Ibarrola O., Amil B., Caruson M. M., Chiariotti L., Palacios-Ariza M. A., Hoekstra P. J., Chiang H. Y., Floareș A., Fagiolini A., and Fasano A., Optimizing and Predicting Antidepressant Efficacy in Patients With Major Depressive Disorder Using Multi-Omics Analysis and the Opade AI Prediction Tools, Brain Sciences. (2024) 14, no. 7, 10.3390/brainsci14070658, 39061399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71. Wu J., Singleton S. S., Bhuiyan U., Krammer L., and Mazumder R., Multi-Omics Approaches to Studying Gastrointestinal Microbiome in the Context of Precision Medicine and Machine Learning, Frontiers in Molecular Biosciences. (2024) 10, 1337373, 10.3389/fmolb.2023.1337373, 38313584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72. Parmar K. M., Gaikwad S. L., Dhakephalkar P. K., Kothari R., and Singh R. P., Intriguing Interaction of Bacteriophage-Host Association: An Understanding in the Era of Omics, Frontiers in Microbiology. (2017) 8, 10.3389/fmicb.2017.00559, 2-s2.0-85018240912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73. Dery K. J., Górski A., Miedzybrodzki R., Farmer D. G., and Kupiec-Weglinski J. W., Therapeutic Perspectives and Mechanistic Insights of Phage Therapy in Allotransplantation, Transplantation. (2021) 105, no. 7, 1449–1458, 10.1097/TP.0000000000003565, 33273319. [DOI] [PubMed] [Google Scholar]
  • 74. Fernández Llamas L., Rodríguez González A., and García Suárez M. P., Phage or Foe: An Insight Into the Impact of Viral Predation on Microbial Communities, ISME Journal. (2018) 12, no. 5, 1171–1179, 10.1038/s41396-018-0049-5, 2-s2.0-85040931947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75. Vignoli A., Ghini V., Meoni G., Licari C., Takis P. G., Tenori L., Turano P., and Luchinat C., High-Throughput Metabolomics by 1D NMR, Angewandte Chemie International Edition. (2019) 58, no. 4, 968–994, 10.1002/anie.201804736, 2-s2.0-85056402531, 29999221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76. Tyagi R., Kumar P., and Sharma U., Metabolomics Techniques: A Brief Update, Epigenetics and Metabolomics, 2021, Elsevier, 1–29, 10.1016/B978-0-323-85652-2.00007-5. [DOI] [Google Scholar]
  • 77. Zhao X., Shen M., Jiang X., Shen W., Zhong Q., Yang Y., Tan Y., Agnello M., He X., Hu F., and le S., Transcriptomic and Metabolomics Profiling of Phage–Host Interactions Between Phage PaP1 and Pseudomonas aeruginosa , Frontiers in Microbiology. (2017) 8, 10.3389/fmicb.2017.00548, 2-s2.0-85018182344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78. Papaianni M., Paris D., Woo S. L., Fulgione A., Rigano M. M., Parrilli E., Tutino M. L., Marra R., Manganiello G., Casillo A., Limone A., Zoina A., Motta A., Lorito M., and Capparelli R., Plant Dynamic Metabolic Response to Bacteriophage Treatment After Xanthomonas campestris pv. campestris Infection, Frontiers in Microbiology. (2020) 11, 10.3389/fmicb.2020.00732, 32390981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79. Ribbenstedt A., Ziarrusta H., and Benskin J. P., Development, Characterization and Comparisons of Targeted and Non-Targeted Metabolomics Methods, PloS One. (2018) 13, no. 11, e0207082, 10.1371/journal.pone.0207082, 2-s2.0-85056553024, 30439966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80. Dantas R., Brocchi M., and Pacheco F. T., Chemical-Biology and Metabolomics Studies in Phage-Host Interactions, Microbial Natural Products Chemistry: A Metabolomics Approach, 2023, Springer, 71–100, 10.1007/978-3-031-41741-2_4, 37843806. [DOI] [PubMed] [Google Scholar]
  • 81. Jin M., Cai L., Lu L., Yu M., and Zhang R., Combined Metabolomic and Genomic Analyses Reveal Phage-Specific and Infection Stage-Specific Alterations to marineRoseobactermetabolism, ISME Communications. (2025) 5, no. 1, ycaf047, 10.1093/ismeco/ycaf047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82. Reveglia P., Paolillo C., Ferretti G., De Carlo A., Angiolillo A., Nasso R., Caputo M., Matrone C., Di Costanzo A., and Corso G., Challenges in LC–MS-Based Metabolomics for Alzheimer’s Disease Early Detection: Targeted Approaches Versus Untargeted Approaches, Metabolomics. (2021) 17, no. 9, 10.1007/s11306-021-01828-w, 34453619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83. Chevallereau A., Pons B. J., van Houte S., and Westra E. R., Interactions Between Bacterial and Phage Communities in Natural Environments, Nature Reviews Microbiology. (2022) 20, no. 1, 49–62, 10.1038/s41579-021-00602-y. [DOI] [PubMed] [Google Scholar]
  • 84. Sedighikamal H. and Mashayekhan S., Critical Assessment of Quenching and Extraction/Sample Preparation Methods for Microorganisms in Metabolomics, Metabolomics. (2025) 21, no. 2, 10.1007/s11306-025-02228-0, 40082321. [DOI] [PubMed] [Google Scholar]
  • 85. Chevallereau A., Blasdel B. G., De Smet J., Monot M., Zimmermann M., Kogadeeva M., Sauer U., Jorth P., Whiteley M., Debarbieux L., and Lavigne R., Next-Generation “-Omics” Approaches Reveal a Massive Alteration of Host RNA Metabolism During Bacteriophage Infection of Pseudomonas aeruginosa , PLoS Genetics. (2016) 12, no. 7, e1006134, 10.1371/journal.pgen.1006134, 2-s2.0-84982841164, 27380413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86. Drulis-Kawa Z., Majkowska-Skrobek G., and Maciejewska B., Bacteriophages and Phage-Derived Proteins–Application Approaches, Current Medicinal Chemistry. (2015) 22, no. 14, 1757–1773, 10.2174/0929867322666150209152851, 2-s2.0-84931267864, 25666799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87. Johnson C. H., Ivanisevic J., and Siuzdak G., Metabolomics: Beyond Biomarkers and Towards Mechanisms, Nature Reviews Molecular Cell Biology. (2016) 17, no. 7, 451–459, 10.1038/nrm.2016.25, 2-s2.0-84961231007, 26979502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88. Ankrah N. Y. D., May A. L., Middleton J. L., Jones D. R., Hadden M. K., Gooding J. R., LeCleir G. R., Wilhelm S. W., Campagna S. R., and Buchan A., Phage Infection of an Environmentally Relevant Marine Bacterium Alters Host Metabolism and Lysate Composition, ISME Journal. (2014) 8, no. 5, 1089–1100, 10.1038/ismej.2013.216, 2-s2.0-84899490286, 24304672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89. Kortright K. E., Chan B. K., Koff J. L., and Turner P. E., Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria, Cell Host & Microbe. (2019) 25, no. 2, 219–232, 10.1016/j.chom.2019.01.014, 2-s2.0-85061065666, 30763536. [DOI] [PubMed] [Google Scholar]
  • 90. De Smet J., Zimmermann M., Kogadeeva M., Ceyssens P.-J., Vermaelen W., Blasdel B. et al., High Coverage Metabolomics Analysis Reveals Phage-Specific Alterations to Pseudomonas aeruginosa Physiology During Infection, ISME Journal. (2016) 10, no. 8, 1823–1835, 10.1038/ismej.2016.3, 2-s2.0-84958793786, 26882266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91. Bohannan B. J. and Lenski R. E., Linking Genetic Change to Community Evolution: Insights From Studies of Bacteria and Bacteriophage, Ecology Letters. (2000) 3, no. 4, 362–377, 10.1046/j.1461-0248.2000.00161.x, 2-s2.0-0033878587. [DOI] [Google Scholar]
  • 92. Oechslin F., Resistance Development to Bacteriophages Occurring During Bacteriophage Therapy, Viruses. (2018) 10, no. 7, 10.3390/v10070351, 2-s2.0-85049860926, 29966329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93. Howard-Varona C., Lindback M. M., Bastien G. E., Solonenko N., Zayed A. A., Jang H., Andreopoulos B., Brewer H. M., Glavina del Rio T., Adkins J. N., Paul S., Sullivan M. B., and Duhaime M. B., Phage-Specific Metabolic Reprogramming of Virocells, ISME Journal. (2020) 14, no. 4, 881–895, 10.1038/s41396-019-0580-z, 31896786. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94. Perez-Sepulveda B. M. and Hinton J. C., Functional Transcriptomics for Bacterial Gene Detectives, Microbiology Spectrum. (2018) 6, no. 5, 10–1128, 10.1128/microbiolspec.rwr-0033-2018, 2-s2.0-85054766249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95. Tripathi R., Chakraborty P., and Varadwaj P. K., Unraveling Long Non-Coding RNAs Through Analysis of High-Throughput RNA-Sequencing Data, Non-Coding RNA Research. (2017) 2, no. 2, 111–118, 10.1016/j.ncrna.2017.06.003, 2-s2.0-85061065233, 30159428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96. Vivek A. and Kumar S., Computational Methods for Annotation of Plant Regulatory Non-Coding RNAs Using RNA-seq, Briefings in Bioinformatics. (2021) 22, no. 4, bbaa322, 10.1093/bib/bbaa322, 33333550. [DOI] [PubMed] [Google Scholar]
  • 97. Gaidatzis D., Burger L., Florescu M., and Stadler M. B., Analysis of Intronic and Exonic Reads in RNA-seq Data Characterizes Transcriptional and Post-Transcriptional Regulation, Nature Biotechnology. (2015) 33, no. 7, 722–729, 10.1038/nbt.3269, 2-s2.0-84946197772, 26098447. [DOI] [PubMed] [Google Scholar]
  • 98. Zhang Y., Jiang J., Ma J., Wei Z., Wang Y., Song B., Meng J., Jia G., de Magalhães J. P., Rigden D. J., Hang D., and Chen K., DirectRMDB: A Database of Post-Transcriptional RNA Modifications Unveiled From Direct RNA Sequencing Technology, Nucleic Acids Research. (2023) 51, no. 7, D106–D116, 10.1093/nar/gkac1061, 36382409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99. Letarov A. V. and Letarova M. A., The Burden of Survivors: How Can Phage Infection Impact Non-Infected Bacteria?, International Journal of Molecular Sciences. (2023) 24, no. 3, 10.3390/ijms24032733, 36769055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100. Krin E., Pierlé S. A., Sismeiro O., Jagla B., Dillies M.-A., Varet H., Irazoki O., Campoy S., Rouy Z., Cruveiller S., Médigue C., Coppée J. Y., and Mazel D., Expansion of the SOS Regulon of Vibrio cholerae Through Extensive Transcriptome Analysis and Experimental Validation, BMC Genomics. (2018) 19, no. 1, 1–18, 10.1186/s12864-018-4716-8, 2-s2.0-85047343112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101. Malone L. M., Hampton H. G., Morgan X. C., and Fineran P. C., Type I CRISPR-Cas Provides Robust Immunity but Incomplete Attenuation of Phage-Induced Cellular Stress, Nucleic Acids Research. (2022) 50, no. 1, 160–174, 10.1093/nar/gkab1210, 34928385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102. Barth Z. K., Netter Z., Angermeyer A., Bhardwaj P., and Seed K. D., A Family of Viral Satellites Manipulates Invading Virus Gene Expression and Can Affect Cholera Toxin Mobilization, MSystems. (2020) 5, no. 5, 10.1128/msystems.00358-20, 33051375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103. Boyd C. M., Angermeyer A., Hays S. G., Barth Z. K., Patel K. M., and Seed K. D., Bacteriophage ICP1: A Persistent Predator of Vibrio cholerae , Annual Review of Virology. (2021) 8, no. 1, 285–304, 10.1146/annurev-virology-091919-072020, 34314595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104. Netter Z., Dunham D. T., and Seed K. D., Adaptation to Bile and Anaerobicity limitsVibrio choleraephage Adsorption, Mbio. (2023) 14, no. 6, e01985-23, 10.1128/mbio.01985-23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105. Molina-Mora J. A., Chinchilla-Montero D., Chavarría-Azofeifa M., Ulloa-Morales A. J., Campos-Sánchez R., Mora-Rodríguez R., Shi L., and García F., Transcriptomic Determinants of the Response of ST-111 Pseudomonas aeruginosa AG1 to Ciprofloxacin Identified by a Top-Down Systems Biology Approach, Scientific Reports. (2020) 10, no. 1, 13717, 10.1038/s41598-020-70581-2, 32792590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106. Brandão A. C., Putzeys L., Pires D. P., Voet M., Paeshuyse J., Azeredo J., and Lavigne R., Impact of Phage Predation on P. aeruginosa Adhered to Human Airway Epithelium: Major Transcriptomic Changes in Metabolism and Virulence-Associated Genes, RNA Biology. (2023) 20, no. 1, 235–247, 10.1080/15476286.2023.2216065, 37226433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107. Graves P. R. and Haystead T. A., Molecular Biologist’s Guide to Proteomics, Microbiology and Molecular Biology Reviews. (2002) 66, no. 1, 39–63, 10.1128/MMBR.66.1.39-63.2002, 2-s2.0-0036200945, 11875127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108. Howard-Varona C., Hargreaves K. R., Solonenko N. E., Markillie L. M., White R. A., Brewer H. M., Ansong C., Orr G., Adkins J. N., and Sullivan M. B., Multiple Mechanisms Drive Phage Infection Efficiency in Nearly Identical Hosts, ISME Journal. (2018) 12, no. 6, 1605–1618, 10.1038/s41396-018-0099-8, 2-s2.0-85044262346, 29568113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109. Gygi S. P., Corthals G. L., Zhang Y., Rochon Y., and Aebersold R., Evaluation of Two-Dimensional Gel Electrophoresis-Based Proteome Analysis Technology, Proceedings of the National Academy of Sciences. (2000) 97, no. 17, 9390–9395, 10.1073/pnas.160270797, 2-s2.0-0034662907, 10920198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110. Baldwin M. A., Protein Identification by Mass Spectrometry, Molecular & Cellular Proteomics. (2004) 3, no. 1, 1–9, 10.1074/mcp.R300012-MCP200, 2-s2.0-2542640024. [DOI] [PubMed] [Google Scholar]
  • 111. Abril A. G., Carrera M., Böhme K., Barros-Velázquez J., Cañas B., Rama J.-L. R., Villa T. G., and Calo-Mata P., Proteomic Characterization of Bacteriophage Peptides From the Mastitis Producer Staphylococcus aureus by LC-ESI-MS/MS and the Bacteriophage Phylogenomic Analysis, Foods. (2021) 10, no. 4, 10.3390/foods10040799, 33917943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112. Brandi J., Noberini R., Bonaldi T., and Cecconi D., Advances in Enrichment Methods for Mass Spectrometry-Based Proteomics Analysis of Post-Translational Modifications, Journal of Chromatography A. (2022) 1678, 463352, 10.1016/j.chroma.2022.463352, 35896048. [DOI] [PubMed] [Google Scholar]
  • 113. Longin H., Broeckaert N., van Noort V., Lavigne R., and Hendrix H., Posttranslational Modifications in Bacteria During Phage Infection, Current Opinion in Microbiology. (2024) 77, 102425, 10.1016/j.mib.2024.102425, 38262273. [DOI] [PubMed] [Google Scholar]
  • 114. Taylor V. L., Fitzpatrick A. D., Islam Z., and Maxwell K. L., The Diverse Impacts of Phage Morons on Bacterial Fitness and Virulence, Advances in Virus Research. (2019) 103, 1–31, 10.1016/bs.aivir.2018.08.001, 2-s2.0-85054131595, 30635074. [DOI] [PubMed] [Google Scholar]
  • 115. Hrebík D., Štveráková D., Škubník K., Füzik T., Pantůček R., and Plevka P., Structure and Genome Ejection Mechanism ofStaphylococcus aureusphage P68, Science Advances. (2019) 5, no. 10, eaaw7414, 10.1126/sciadv.aaw7414, 2-s2.0-85073872322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116. Klumpp J., Dorscht J., Lurz R., Bielmann R., Wieland M., Zimmer M., Calendar R., and Loessner M. J., The Terminally Redundant, Nonpermuted Genome of Listeria Bacteriophage A511: A Model for the SPO1-Like Myoviruses of Gram-Positive Bacteria, Journal of Bacteriology. (2008) 190, no. 17, 5753–5765, 10.1128/JB.00461-08, 2-s2.0-50249163139, 18567664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117. Bleriot I., Blasco L., Pacios O., Fernández-García L., López M., Ortiz-Cartagena C., Barrio-Pujante A., Fernández-Cuenca F., Pascual Á., Martínez-Martínez L., Oteo-Iglesias J., and Tomás M., Proteomic Study of the Interactions Between Phages and the Bacterial HostKlebsiella pneumoniae , Microbiology Spectrum. (2023) 11, no. 2, e03974-22, 10.1128/spectrum.03974-22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118. Young J. C., Dill B. D., Pan C., Hettich R. L., Banfield J. F., Shah M., Fremaux C., Horvath P., Barrangou R., and VerBerkmoes N. C., Phage-Induced Expression of CRISPR-Associated Proteins Is Revealed by Shotgun Proteomics in Streptococcus thermophilus , PloS One. (2012) 7, no. 5, e38077, 10.1371/journal.pone.0038077, 2-s2.0-84861632698, 22666452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119. Segall A. M., Roach D. R., and Strathdee S. A., Stronger Together? Perspectives on Phage-Antibiotic Synergy in Clinical Applications of Phage Therapy, Current Opinion in Microbiology. (2019) 51, 46–50, 10.1016/j.mib.2019.03.005, 2-s2.0-85067244098, 31226502. [DOI] [PubMed] [Google Scholar]
  • 120. Cucić S., Putzeys L., Boon M., Lepp D., Lavigne R., Khursigara C. M., and Anany H., Multi-Omics Characterization of a Lytic Phage targetingListeria monocytogenes , MSystems. (2025) 10, no. 7, e00587-25, 10.1128/msystems.00587-25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121. Wani N. and Raza K., Integrative Approaches to Reconstruct Regulatory Networks From Multi-Omics Data: A Review of State-of-the-Art Methods, Computational Biology and Chemistry. (2019) 83, 107120, 10.1016/j.compbiolchem.2019.107120, 2-s2.0-85071776903, 31499298. [DOI] [PubMed] [Google Scholar]
  • 122. Sehra S. S. and Sehra S. K., Conceptual Translation as a Part of Gene Expression, International Journal of Computers & Technology. (2012) 3, 503–505. [Google Scholar]
  • 123. Crick F., Central Dogma of Molecular Biology, Nature. (1970) 227, no. 5258, 561–563, 10.1038/227561a0, 2-s2.0-0014937223. [DOI] [PubMed] [Google Scholar]
  • 124. Chakraborty S., Hosen M. I., Ahmed M., and Shekhar H. U., Onco-Multi-OMICS Approach: A New Frontier in Cancer Research, BioMed Research International. (2018) 2018, no. 1, 9836256, 10.1155/2018/9836256, 2-s2.0-85055409827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 125. Chen Z.-Z. and Gerszten R. E., Metabolomics and Proteomics in Type 2 Diabetes, Circulation Research. (2020) 126, no. 11, 1613–1627, 10.1161/CIRCRESAHA.120.315898, 32437301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126. Santiago-Rodriguez T. M. and Hollister E. B., Multi ‘Omic Data Integration: A Review of Concepts, Considerations, and Approaches, Seminars in Perinatology. (2021) 45, no. 6, 151456, 10.1016/j.semperi.2021.151456. [DOI] [PubMed] [Google Scholar]
  • 127. Roucourt B. and Lavigne R., The Role of Interactions Between Phage and Bacterial Proteins Within the Infected Cell: A Diverse and Puzzling Interactome, Environmental Microbiology. (2009) 11, no. 11, 2789–2805, 10.1111/j.1462-2920.2009.02029.x, 2-s2.0-70350442760, 19691505. [DOI] [PubMed] [Google Scholar]
  • 128. Mariano R., Wuchty S., Vizoso-Pinto M. G., Häuser R., and Uetz P., The Interactome of Streptococcus pneumoniae and Its Bacteriophages Show Highly Specific Patterns of Interactions Among Bacteria and Their Phages, Scientific Reports. (2016) 6, no. 1, 24597, 10.1038/srep24597, 2-s2.0-84971669605, 27103053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 129. Zhao X., Chen C., Shen W., Huang G., Le S., Lu S., Li M., Zhao Y., Wang J., Rao X., and Li G., Global Transcriptomic Analysis of Interactions Between Pseudomonas aeruginosa and Bacteriophage PaP3, Scientific Reports. (2016) 6, no. 1, 19237, 10.1038/srep19237, 2-s2.0-84954158439, 26750429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130. Yuan Y. and Gao M., Proteomic Analysis of a Novel Bacillus Jumbo Phage Revealing Glycoside Hydrolase as Structural Component, Frontiers in Microbiology. (2016) 7, 10.3389/fmicb.2016.00745, 2-s2.0-84973537710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 131. Veses-Garcia M., Liu X., Rigden D. J., Kenny J. G., McCarthy A. J., and Allison H. E., Transcriptomic Analysis of Shiga-Toxigenic Bacteriophage Carriage Reveals a Profound Regulatory Effect on Acid Resistance in Escherichia coli , Applied and Environmental Microbiology. (2015) 81, no. 23, 8118–8125, 10.1128/AEM.02034-15, 2-s2.0-84946073992, 26386055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 132. Sangha K. K., Kumar B. S., Agrawal R. K., Deka D., and Verma R., Proteomic Characterization of Lytic Bacteriophages ofStaphylococcus aureusIsolated From Sewage Affluent of India, International Scholarly Research Notices. (2014) 2014, no. 1, 265298, 10.1155/2014/265298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133. Niu Y. D., Stanford K., Kropinski A. M., Ackermann H.-W., Johnson R. P., She Y.-M., Ahmed R., Villegas A., and McAllister T. A., Genomic, Proteomic and Physiological Characterization of a T5-Like Bacteriophage for Control of Shiga Toxin-Producing Escherichia coli O157: H7, PLoS One. (2012) 7, no. 4, e34585, 10.1371/journal.pone.0034585, 2-s2.0-84859703341, 22514640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 134. Tamakoshi M., Murakami A., Sugisawa M., Tsuneizumi K., Takeda S., Saheki T., Izumi T., Akiba T., Mitsuoka K., Toh H., Yamashita A., Arisaka F., Hattori M., Oshima T., and Yamagishi A., Genomic and Proteomic Characterization of the Large Myoviridae Bacteriophage ϕTMA of the Extreme Thermophile Thermus thermophilus, Bacteriophage. (2011) 1, no. 3, 152–164, 10.4161/bact.1.3.16712, 22164349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 135. Seal B. S., Fouts D. E., Simmons M., Garrish J. K., Kuntz R. L., Woolsey R., Schegg K. M., Kropinski A. M., Ackermann H. W., and Siragusa G. R., Clostridium perfringens Bacteriophages ΦCP39O and ΦCP26F: Genomic Organization and Proteomic Analysis of the Virions, Archives of Virology. (2011) 156, no. 1, 25–35, 10.1007/s00705-010-0812-z, 2-s2.0-78650763593, 20963614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 136. Jain R. and Srivastava R., Metabolic Investigation of Host/Pathogen Interaction Using MS2-Infected Escherichia coli , BMC Systems Biology. (2009) 3, no. 1, 10.1186/1752-0509-3-121, 2-s2.0-76349088732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 137. Łobocka M., Dąbrowska K., and Górski A., Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future, Challenges and Future. BioDrugs. (2021) 35, no. 3, 255–280, 10.1007/s40259-021-00480-z, 33881767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 138. Gelman D., Yerushalmy O., Alkalay-Oren S., Rakov C., Ben-Porat S., Khalifa L., Adler K., Abdalrhman M., Coppenhagen-Glazer S., Aslam S., Schooley R. T., Nir-Paz R., and Hazan R., Clinical Phage Microbiology: A Suggested Framework and Recommendations for the In-Vitro Matching Steps of Phage Therapy, Lancet Microbe. (2021) 2, no. 10, e555–e563, 10.1016/S2666-5247(21)00127-0, 35544180. [DOI] [PubMed] [Google Scholar]
  • 139. Pal N., Sharma P., Kumawat M., Singh S., Verma V., Tiwari R. R., Sarma D. K., Nagpal R., and Kumar M., Phage Therapy: An Alternative Treatment Modality for MDR Bacterial Infections, Infectious Diseases. (2024) 56, no. 10, 785–817, 10.1080/23744235.2024.2379492. [DOI] [PubMed] [Google Scholar]
  • 140. Skliros D., Kalatzis P. G., Kalloniati C., Komaitis F., Papathanasiou S., Kouri E. D., Udvardi M. K., Kokkari C., Katharios P., and Flemetakis E., The Development of Bacteriophage Resistance in Vibrio alginolyticus Depends on a Complex Metabolic Adaptation Strategy, Viruses. (2021) 13, no. 4, 10.3390/v13040656, 33920240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 141. Fondi M. and Liò P., Multi -omics and Metabolic Modelling Pipelines: Challenges and Tools for Systems Microbiology, Microbiological Research. (2015) 171, 52–64, 10.1016/j.micres.2015.01.003, 2-s2.0-84930045803, 25644953. [DOI] [PubMed] [Google Scholar]
  • 142. Ma A., McDermaid A., Xu J., Chang Y., and Ma Q., Integrative Methods and Practical Challenges for Single-Cell Multi-Omics, Trends in Biotechnology. (2020) 38, no. 9, 1007–1022, 10.1016/j.tibtech.2020.02.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 143. Arıkan M. and Muth T., Integrated Multi-Omics Analyses of Microbial Communities: A Review of the Current State and Future Directions, Molecular Omics. (2023) 19, no. 8, 607–623, 10.1039/D3MO00089C, 37417894. [DOI] [PubMed] [Google Scholar]
  • 144. Pant S., Choudhari J. K., Pathak R. K., Yadav A. K., and Singh D. B., Biological Big Data Analysis in the Post-Genomic Era: Applications and Limitations, Network Modeling Analysis in Health Informatics and Bioinformatics. (2026) 15, no. 1, 10.1007/s13721-026-00749-9. [DOI] [Google Scholar]
  • 145. Luo Y., Zhao C., and Chen F., Multiomics Research: Principles and Challenges in Integrated Analysis, BioDesign Research. (2024) 6, 10.34133/bdr.0059, 39990095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 146. Nguyen Q.-H., Nguyen H., Oh E. C., and Nguyen T., Current Approaches and Outstanding Challenges of Functional Annotation of Metabolites: A Comprehensive Review, Briefings in Bioinformatics.(2024) 25, no. 6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 147. Lee R. Y., Ng C. W., Rajapakse M. P., Ang N., Yeong J. P. S., and Lau M. C., The Promise and Challenge of Spatial Omics in Dissecting Tumour Microenvironment and the Role of AI, Frontiers in Oncology. (2023) 13, 1172314, 10.3389/fonc.2023.1172314, 37197415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 148. Bressan D., Battistoni G., and Hannon G. J., The Dawn of Spatial Omics, Science. (2023) 381, no. 6657, eabq4964, 10.1126/science.abq4964, 37535749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 149. Morabito A., De Simone G., Pastorelli R., Brunelli L., and Ferrario M., Algorithms and Tools for Data-Driven Omics Integration to Achieve Multilayer Biological Insights: A Narrative Review, Journal of Translational Medicine. (2025) 23, no. 1, 10.1186/s12967-025-06446-x, 40211300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 150. Schwartz T. S., The Promises and the Challenges of Integrating Multi-Omics and Systems Biology in Comparative Stress Biology, Integrative and Comparative Biology. (2020) 60, no. 1, 89–97, 10.1093/icb/icaa026, 32386307. [DOI] [PubMed] [Google Scholar]
  • 151. Hu L., Guo S., Cao M., Xiong L., Ding Z., Kang Y., Zhang B., Cai B., Pei J., and Guo X., Ribo-Seq Analysis-Based Elucidation of the Dynamic Translation Landscape of Yak Ovarian Tissues in Different Reproductive Stages, FASEB Journal. (2025) 39, no. 15, e70924, 10.1096/fj.202500646RR, 40779359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 152. Silverman A., Nashef R., Wasserman R., Noy T., Born S., Yao T., Geng Y., Rotbard H., Levkowitz A., Kaufman Y., Golding I., and Melamed S., Phage-Encoded Small RNA Hijacks Host Replication Machinery to Support the Phage Lytic Cycle, Molecular Cell. (2025) 85, no. 24, 4678–4697.e12, 10.1016/j.molcel.2025.11.019, 41418758. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 153. Lewandowska N., Bloch S., Łukasiak A., Wesołowski W., Węgrzyn G., and Nejman-Faleńczyk B., The Role of Bacteriophage-Derived Small RNA Molecules in Bacterial and Phage Interactions, Viruses. (2025) 17, no. 6, 10.3390/v17060834, 40573425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 154. Marks J. and Meydan S., How Tailored Ribo-seq Methods Probe Unique Translation Events, RNA. (2026) 32, no. 3, 276–289, 10.1261/rna.080654.125, 41397878. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 155. Zhang Y., Thomas J. P., Korcsmaros T., and Gul L., Integrating Multi-Omics to Unravel Host-Microbiome Interactions in Inflammatory Bowel Disease, Cell Reports Medicine. (2024) 5, no. 9, 101738, 10.1016/j.xcrm.2024.101738, 39293401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 156. Lu J., Zhang W., He Y., Jiang M., Liu Z., Zhang J., Zheng L., Zhou B., Luo J., He C., Shan Y., Zhang R., Fan K. L., Fang B., and Wan C., Multi-Omics Decodes Host-Specific and Environmental Microbiome Interactions in Sepsis, Frontiers in Microbiology. (2025) 16, 1618177, 10.3389/fmicb.2025.1618177, 40641871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 157. Swart A., Caspi R., Paley S., and Karp P. D., Visual Analysis of Multi-Omics Data, 2024, bio Rxiv. 2024: 2024.04.23.590648. [DOI] [PMC free article] [PubMed]
  • 158. Li R., Li L., Xu Y., and Yang J., Machine Learning Meets Omics: Applications and Perspectives, Briefings in Bioinformatics. (2022) 23, no. 1, bbab460, 10.1093/bib/bbab460, 34791021. [DOI] [PubMed] [Google Scholar]
  • 159. Sathyanarayanan A., Mueller T. T., Moni M. A., Schueler K., Baune B. T., Lio P., Mehta D., Baune B. T., Dierssen M., Ebert B., and Fabbri C., Multi-Omics Data Integration Methods and Their Applications in Psychiatric Disorders, European Neuropsychopharmacology. (2023) 69, 26–46, 10.1016/j.euroneuro.2023.01.001. [DOI] [PubMed] [Google Scholar]
  • 160. Cobián Güemes A. G., Lim Y. W., Quinn R. A., Conrad D. J., Benler S., Maughan H., Edwards R., Brettin T., Cantú V. A., Cuevas D., Hamidi R., Dorrestein P., Rohwer F., Hunter R., and Bean H., Cystic Fibrosis Rapid Response: Translating Multi-Omics Data Into Clinically Relevant Information, MBio. (2019) 10, no. 2, 10.1128/mbio.00431-19, 2-s2.0-85064994454, 30992350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 161. Iszatt J. J., Larcombe A. N., Chan H.-K., Stick S. M., Garratt L. W., and Kicic A., Phage Therapy for Multi-Drug Resistant Respiratory Tract Infections, Viruses. (2021) 13, no. 9, 10.3390/v13091809, 34578390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 162. Wang X., Xu G., Liu X., Liu Y., Zhang S., and Zhang Z., Multiomics: Unraveling the Panoramic Landscapes of SARS-CoV-2 Infection, Cellular & Molecular Immunology. (2021) 18, no. 10, 2313–2324, 10.1038/s41423-021-00754-0, 34471261. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data sharing is not applicable to this article, as no datasets were generated or analyzed during the current study.


Articles from BioMed Research International are provided here courtesy of Wiley

RESOURCES